bpc 157 pubmed Bpc-157 | C62H98N16O22 | CID 9941957 Gastric pentadecapeptide body protection compound
Description
Additional Risks Associated With More Intensive Cell Therapies Different cell therapies have different risk profiles
In the SURMOUNT-1 trial, 24-26% of participants experienced nausea at some point during the study, most commonly during dose escalation phases
I am trying the B-12 just recently and it is great as well
[1] Intramuscular administration bypasses absorption issues, making it effective regardless of the underlying cause
